Table III.

Published sensitivity rates for SLN biopsy.

First author (ref.)	Year	No. of patients with oral SCC/no. of patients	Cancer	T-Stage	No. of detected CM by SLN/no. of all CM	Sensitivity, %
Hyde et al (38)	2003	19/19	Oral cancer	1–4	3/4	75
Gallegos et al (33)	2005	48/48	Oral cancer	1–2	13/17	77
Frerich et al (39)	2007	28/40	Oropharyngeal cancer	1–2	8/10	80
Chone et al (11)	2008	24/35	Oropharyngeal cancer	1–3	9/11	82
Werner et al (30)	2004	11/90	Oropharyngeal cancer	1–3	20/23	87
Civantos et al (23)	2010	140/140	Oral cancer	1–2	34/40	90
Tschopp et al (40)	2005	25/31	Oropharyngeal cancer	1–3	14/15	93
Shoaib et al (41)	2001	37/37	Oral cancer	1–4	16/17	94
Ionna et al (42)	2002	40/40	Oral cancer	1–2	4/4	100
Höft et al (43)	2004	22/50	Oropharyngeal cancer	1–4	12/12	100
Bilde et al (44)	2008	51/51	Oral cancer	1–2	11/11	100
Current study	2015	10/10	Oral cancer	1–2	4/5	80

SLN, sentinel lymph node; CM, cervical metastases; T, tumor.